178 related articles for article (PubMed ID: 32668853)
1. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
Kobayashi S; Yasu T; Momo K; Ohno N
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
[TBL] [Abstract][Full Text] [Related]
2. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
3. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
5. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
6. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
7. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
8. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
9. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
10. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.
Bielack S; Fox CP; Hoang-Xuan K; Giró-Perafita A; Rizzari C
Health Sci Rep; 2024 Jan; 7(1):e1749. PubMed ID: 38186937
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
[TBL] [Abstract][Full Text] [Related]
12. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
13. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
14. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
[TBL] [Abstract][Full Text] [Related]
16. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing delayed high-dose methotrexate excretion and its correlation with adverse reactions after treatment in children with malignant hematological tumors.
Yu L; Shen J; Li H; Zhang M; Wang Z; Gao Y; Chen J; Li J
Transl Pediatr; 2024 Feb; 13(2):300-309. PubMed ID: 38455749
[TBL] [Abstract][Full Text] [Related]
19. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.
Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A
Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862
[TBL] [Abstract][Full Text] [Related]
20. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]